Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Abstract Text:

Peter C Appelbaum,Peter C Appelbaum,Peter C Appelbaum,

Vancomycin and other glycopeptide antibiotics are the current mainstay of therapy for infections caused by methicillin-resistant Staphylococcus aureus (MRSA). However, the high prevalence of MRSA has led to increased use of vancomycin in chronic and seriously ill patients and has resulted in the emergence of MRSA with reduced susceptibility to glycopeptides. Multiple MRSA phenotypes demonstrate reduced susceptibility to glycopeptides. According to the Clinical and Laboratory Standards Institute, vancomycin-intermediate S. aureus (VISA) are now those isolates with minimum inhibitory concentrations (MICs) between 4 microg/mL and 8 microg/mL, whilst heterogeneous VISA (hVISA) strains appear to be susceptible to vancomycin but contain a subpopulation of cells with reduced susceptibility to vancomycin (MICs > or = 4 microg/mL). At this time, MICs for these strains are reported to range between 1 microg/mL and 2 microg/mL. Vancomycin-resistant S. aureus (VRSA) are defined as those having MICs > or = 16 microg/mL. The detection of reduced susceptibility to vancomycin by routine susceptibility testing is unreliable and vancomycin non-susceptibility is most probably being underreported. Reports of reduced clinical efficacy associated with vancomycin MICs between 1 microg/mL and 2 microg/mL have been published. Patients most at risk of infection by hVISA, VISA and VRSA appear to be those with previous exposure to vancomycin. VRSA appears in the elderly and those with chronic leg or decubitus ulcers mainly containing vancomycin-resistant enterococci, which were probably the donor organism of the vanA gene to S. aureus. All MRSA strains recovered from patients whose infections do not respond to vancomycin treatment should be tested accurately for vancomycin susceptibility if these phenotypes are not to be missed. Treatment options for infections due to MRSA with reduced susceptibility to vancomycin are limited. Rapid identification of patients harbouring VRSA, VISA or hVISA as well as prompt isolation and adherence to infection control protocols are paramount in controlling the dissemination of these pathogens.

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Publishing Authors By Initials

PC Appelbaum,PC Appelbaum,PC Appelbaum,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Journal Published:

PUBLICATION TYPE: Review

Journal: International journal of antimicrobial agents

VOLUME: 30

Page Numbers: 398-408

Journal Abbreviation: Int. J. Antimicrob. Agents

ISSN: 0924-8579

DAY: 20

MONTH: 09

YEAR: 2007

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9111860

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

AFFILIATION: Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA. pappelbaum@psu.edu

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Antimicrob Agents

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus MRSA Related Publications

• A direct comparison of research decision-making capacity: Schizophrenia/schizoaffective, medically ill, and non-ill subjects.
• Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
• Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
• Agnogenic myeloid metaplasia: a case report.
• Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
• Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
• Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
• Coherent Spin Transport through a 350 Micron Thick Silicon Wafer.
• Commentary: the use of restraint and seclusion in correctional mental health.
• Comparative Antianaerobic Activities of Doripenem Determined by MIC and Time-Kill Analysis.
• Development of autonomy: role of walking onset and its timing.
• Disclosure of information to potential subjects on research recruitment web sites.
• Ethics and forensic psychiatry: translating principles into practice.
• Genetic characterization of erythromycin- and methicillin-resistant community-acquired Staphylococcus aureus isolated from children in Texas.
• Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow.
• Hormone receptors in breast cancer.
• Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.
• In Vitro Activity of DC-159a, a New Broad-Spectrum Fluoroquinolone, Compared with That of Other Agents against Drug-Susceptible and -Resistant Pneumococci.
• In Vitro Capability of Faropenem To Select for Resistant Mutants of Streptococcus pneumoniae and Haemophilus influenzae.
• Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML).
• Law & psychiatry: Death row delusions: when is a prisoner competent to be executed?
• Law & psychiatry: privilege in the federal courts: should there be a "dangerous patient exception"?
• Law & psychiatry: sex offenders in the community: are current approaches counterproductive?
• Molecular characterization of multidrug-resistant Streptococcus pneumoniae isolates in Korea. The Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study Group.
• Patients' competence to consent to treatment.
• Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: A southwest oncology group study (SWOG-9500).
• Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
• Retrolental fibroplasia; a disease of the eyes in premature infant; with report of a case.
• Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
• The voluntary patient--a psychiatrist's perspective.